Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer

&NA; The progression of prostatic adenocarcinoma from localized disease to metastatic carcinoma appears to be a multi‐step sequence. The expression of common oncogenes/oncosuppressor genes and the mediating effect of neuroendocrine tumor cells may play a role in this progression. The expression of the more frequently investigated oncogenes/oncosuppressor genes (p53, c‐myc, c‐erbB‐2, bcl‐2) and the presence of neuroendocrine cells were assessed in prostatic cancer tissue from patients with localized and metastatic cancer. These oncogenes/oncosuppressor genes were evaluated according to tumor stage and grade and their relationship to one another. Grade was not related to any of the oncogene markers or to the presence of neuroendocrine cells. Advancing stage was associated with a significant increase in p53 expression, while other markers remained constant in all stages. Neuroendocrine cells, p53, c‐myc, c‐erbB‐2 and bcl‐2 were rarely co‐expressed at any stage of prostate cancer.

[1]  R. Cohen,et al.  BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. , 1994, Archives of pathology & laboratory medicine.

[2]  S. Fosså,et al.  Prostatic carcinoma: a multivariate analysis of prognostic factors. , 1994, British Journal of Cancer.

[3]  C. Cordon-Cardo,et al.  Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. , 1994, The Journal of urology.

[4]  F. Bosman,et al.  Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer , 1994, International journal of cancer.

[5]  E. Gelmann,et al.  p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.

[6]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[7]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[8]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[9]  R. Cohen,et al.  Neuro-endocrine cells--a new prognostic parameter in prostate cancer. , 1991, British journal of urology.

[10]  S. Maygarden,et al.  Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. , 1991, Human pathology.

[11]  R. Cohen,et al.  Prostatic carcinoma: histological and immunohistological factors affecting prognosis. , 1990, British journal of urology.

[12]  G. Evan,et al.  Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia. , 1987, British Journal of Cancer.

[13]  D. Paulson,et al.  Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma , 1981, Cancer.

[14]  D. Allred,et al.  Recessive oncogenes. , 1993, Cancer.

[15]  R. Sadasivan,et al.  Mutant p53 expression in prostate carcinoma , 1993, The Prostate.

[16]  R. Weinberg.  Oncogenes and the molecular origins of cancer , 1989 .

[17]  J D Siegal,et al.  Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.

[18]  P. Smith,et al.  Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. , 1987, Urologia internationalis.